Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01279538 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01279538 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 50 participants.
The verdict
NCT01279538, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the Pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ASKP1240 when administered to subjects who received a de novo kidney transplant.
Interventions
- DRUG Placebo
- DRUG bleselumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-11-17 |
| Est. Completion | 2012-01-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01279538
The ClinicalTrials.gov registry entry for NCT01279538 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01279538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01279538 about?
NCT01279538 is a clinical study titled "A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation". The purpose of the study is to assess the Pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ASKP1240 when administered to subjects who received a de novo kidney transplant.
What is the current status of trial NCT01279538?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2010-11-17. Estimated completion is 2012-01-23.
What interventions are being tested in trial NCT01279538?
The interventions under investigation include: Placebo (DRUG), bleselumab (DRUG).
Who is sponsoring clinical trial NCT01279538?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.